Preu Bohlig, under the responsibility of Munich’s Partner Dr Alexander Meier, advised Moderna on legal aspects related to the grant of the marketing authorisation for its COVID-19 Vaccine by the European Commission and Moderna’s interactions with the European Medicines Agency (EMA). In addition, Preu Bohlig advised on regulatory requirements related to the supply of Moderna’s COVID-19 Vaccine in the EU/EEA and also coordinated the related legal support across all EU/EEA Member States.
Moderna is pioneering a new class of drugs, the messenger RNA Therapeutics (mRNAs), with the potential to treat a wide range of diseases and conditions. Moderna developed a vaccine against COVID-19 for which the European Commission granted a conditional marketing authorization on 6 January 2021 under the name „COVID-19 Vaccine Moderna“ following the scientific assessment of the EMA.
Team of Preu Bohlig: Dr Alexander Meier (Partner), Dr Alexander Hödemaker (Associate).